BioCentury
ARTICLE | Clinical News

GS-9876: Ph II started

April 11, 2017 7:38 PM UTC

Gilead began a double-blind, placebo-controlled, international Phase II trial to evaluate oral 200 mg filgotinib (GLPG0634, GS-6034), 30 mg GS-9876 or 40 mg tirabrutinib (GS-4059, ONO-4059) each alone...

BCIQ Company Profiles

Gilead Sciences Inc.

BCIQ Target Profiles

Spleen tyrosine kinase (SYK)